Physicians Notified About Elevated Fracture Rate Among Women in Rosiglitazone Trials

The maker of rosiglitazone is notifying health care professionals about an increased rate of fractures found in women participating in two large, long-term controlled trials of the drug, and the company is advising providers to consider these findings when prescribing rosiglitazone.